Since early March 2020, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to the Covid-19 pandemic. Many companies have delayed the initiation of planned trials or withdrawn them completely and others have suspended enrollment in their ongoing trials or terminated the trials altogether. The majority of trial disruptions can be attributed to patient safety measures, strict lockdown requirements, social distancing procedures and the high demand on medical professionals to treat Covid-19 patients.

As the initial peak of the virus started declining, many trials were set to resume activity. However, the number of confirmed Covid-19 cases is increasing again due to the emergence of new variants.

The Covid-19 Dashboard on GlobalData’s Pharma Intelligence Center dynamically tracks both disrupted and resumed trials.

As of August 19, the number of resumed trials is currently at 1,086. Out of these trials, 52.7% are currently recruiting participants, 21.9% have completed recruitment but are still ongoing and 0.2% have yet to start recruiting subjects. The figure below shows that the number of trials resuming has increased slightly.

The US has the highest proportion of resumed trials at 69.3%, followed by the UK at 9.3%, Spain at 7.5%, France at 7.1% and Germany at 6.8%.